Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
29 results
  • Lymphoma, Cellular Therapy

18-455          Phase III

A global randomized multicenter phase 3 trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk transplant-eligible relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (Transform) (View details on

  • Lung Cancer, Lymphoma, Head and Neck Cancer, Gastric (Stomach) Cancer

17-674          Phase I

A Phase 1, Dose Escalation Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma (View details on

  • Cellular Therapy, Lymphoma

20-001          Phase I

A Phase 1, Multicenter, Open-Label Study of CC-97540, CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (View details on

  • Lymphoma, Cellular Therapy

15-404          Phase I

A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) (View details on

  • Lymphoma

15-229          Phase I

A Phase 1, Open-Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects with High Risk (IPI 3 Or More) Previously Untreated Diffuse Large B-Cell Lymphoma or Grade 3B Follicular Lymphoma (View details on

  • Hodgkin's Disease, Lymphoma

19-113          Phase II

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) (View details on

  • Lymphoma

19-743          Phase II

A Phase 2 Study of MRD Adapted Therapy with Venetoclax-Obinutuzumab in Patients with High or Intermediate Risk Relapsed or Refractory CLL, with Addition of Ibrutinib in Patients who Fail to Achieve MRD Eradication (View details on

  • Lymphoma

20-333          Phase II

A Phase 2 Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects with Chronic Lymphocytic Leukemia (CLL) Currently Treated with Ibrutinib or Venetoclax (View details on

  • Leukemia, Lymphoma, Cellular Therapy

19-087          Phase I

A Phase I Clinical Trial with CAR-37 T Cells for the Treatment of Patients with Relapsed or Refractory CD37+ Hematologic Malignancies (View details on

Showing 1 - 10 of 29 results